← Every company
Alnylam Pharmaceuticals Inc Lobbying
What Alnylam Pharmaceuticals Inc discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.
ALNY on carbonthat →Disclosed spend
$1.4M
across every filing on file
Filings
12
Years covered
1
Firms retained
4
What it lobbies about
Medicare/MedicaidPharmacyTrade (domestic/foreign)Medical/Disease Research/Clinical Labs
12 filings
Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.
| Period | Lobbying for them | Disclosed |
|---|---|---|
| 20262nd Quarter (Apr 1 - June 30) | ALNYLAM PHARMACEUTICALS, INC.PharmacyMedicare/Medicaid | $450K |
| 20261st Quarter (Jan 1 - Mar 31) | ALNYLAM PHARMACEUTICALS, INC.Medicare/MedicaidTrade (domestic/foreign) | $430K |
| 20261st Quarter (Jan 1 - Mar 31) | SPLITOAK STRATEGIES LLCMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | CAPITOL COUNSEL LLCMedical/Disease Research/Clinical Labs | $60K |
| 20262nd Quarter (Apr 1 - June 30) | TODD STRATEGY GROUPMedicare/Medicaid | $60K |
| 20262nd Quarter (Apr 1 - June 30) | TIBER CREEK GROUPMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | TIBER CREEK GROUPMedicare/Medicaid | $60K |
| 20262nd Quarter (Apr 1 - June 30) | SPLITOAK STRATEGIES LLCMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | TODD STRATEGY GROUPMedicare/Medicaid | $60K |
| 20261st Quarter (Jan 1 - Mar 31) | LMH STRATEGIC SOLUTIONSMedicare/Medicaid | $50K |
| 20262nd Quarter (Apr 1 - June 30) | LMH STRATEGIC SOLUTIONSMedicare/Medicaid | $50K |
| 20262nd Quarter (Apr 1 - June 30) | CAPITOL COUNSEL LLCMedical/Disease Research/Clinical Labs | $30K |
A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.
More on ALNY
Company overviewEverything on ALNY in one place, with the price.SEC filingsWhat ALNY's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ALNY's own officers and directors buy and sell.Executive payWhat ALNY awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in ALNY.Funds holding itWhich funds and ETFs hold ALNY, and how big a bet.Who lobbies for itThe lobbyists on ALNY's account, and who they worked for.PatentsWhat ALNY is filing at the patent office.